Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
The variability of serum osteoprotegerin (OPG) and soluble RANKL (sRANKL) along the 24-h cycle was assessed in 20 healthy women. No rhythmic variations of serum OPG, sRANKL or sRANKL/OPG ratio were detected as a group phenomenon. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL.


BACKGROUND
Physiological bone turnover shows diurnal variations. The aim of the study was to assess variability of OPG and sRANKL serum levels along the 24-h cycle.


METHODS
Blood was collected from 20 healthy women (median age 31 years, range 25-65 years) at 4-h intervals between 08:00 and 24:00 and at 2-h intervals between 24:00 and 08:00. Serum albumin, cortisol, osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX), OPG and total sRANKL were measured. Temporal variations were assessed by the COSINOR model.


RESULTS
Circadian rhythms of cortisol and albumin documented a normal synchronization within the circadian structure. Serum OC and CTX showed rhythmic variations, peaking at night-time. Rhythmic variations of serum OPG, sRANKL and sRANKL/OPG ratio were not detected as a group phenomenon. On an individual basis, rhythmic changes were detected in ten patients for OPG and eight patients for sRANKL, with very small amplitudes and heterogeneous acrophases.


CONCLUSIONS
The absence of consistent rhythmic variations of circulating OPG and sRANKL levels may reflect the absence of rhythmic variations of their expression in the bone microenvironment. Were this the case, the nocturnal rise of bone resorption should be accounted for by different, not RANKL/OPG-mediated factors. Since circulating OPG and sRANKL may derive from sources other than bone, rhythmicity could be masked by non-rhythmic or non-synchronized rhythmic expression in these sources. Timing of sampling is unlikely to influence the results of measurements of circulating OPG and sRANKL.
Dovio
A
A
Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. andrea.dovio@unito.it
Generali
D
D
Tampellini
M
M
Berruti
A
A
Tedoldi
S
S
Torta
M
M
Bonardi
S
S
Tucci
M
M
Allevi
G
G
Aguggini
S
S
Bottini
A
A
Dogliotti
L
L
Angeli
A
A
D000328:Adult; D000368:Aged; D016723:Bone Remodeling / Q000502:physiology*; D002940:Circadian Rhythm; D024042:Collagen Type I / Q000097:blood; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D053244:Osteoprotegerin / Q000097:blood*; D053245:RANK Ligand / Q000097:blood*; D012709:Serum Albumin / Q000737:chemistry
D024042:Collagen Type I; D053244:Osteoprotegerin; D053245:RANK Ligand; D012709:Serum Albumin; D015675:Osteocalcin; D006854:Hydrocortisone
Biochem Biophys Res Commun. 1998 Apr 17;245(2):382-7
9571159
Biochem Biophys Res Commun. 2000 Sep 7;275(3):768-75
10973797
J Endocrinol Invest. 2005;28(10 Suppl):14-22
16550717
Int J Biochem Cell Biol. 2007;39(6):1077-81
17174136
J Bone Miner Res. 2007 Mar;22(3):357-65
17144790
Calcif Tissue Int. 1997 May;60(5):419-23
9115158
J Clin Endocrinol Metab. 2007 May;92(5):1803-8
17327380
J Biol Chem. 2006 Dec 1;281(48):36846-55
17018528
Bone. 2002 Jul;31(1):57-61
12110413
Bone. 2007 Mar;40(3):723-9
17081815
Bone. 2003 Feb;32(2):170-9
12633789
Clin Lab. 2003;49(9-10):461-3
14572201
Bone. 2002 Jan;30(1):307-13
11792602
Biomed Pharmacother. 2005 Oct;59 Suppl 1:S225-8
16275499
Cell. 2005 Sep 9;122(5):803-15
16143109
Ann Clin Biochem. 2000 Jul;37 ( Pt 4):432-46
10902858
Clin Chem. 2003 Dec;49(12):2083-5
14633883
Clin Cancer Res. 2002 Jul;8(7):2306-10
12114435
Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75
15561602
J Clin Endocrinol Metab. 1998 Mar;83(3):751-6
9506720
JAMA. 2004 Jul 28;292(4):490-5
15280347
Bone. 2002 Jul;31(1):62-9
12110414
J Clin Endocrinol Metab. 2005 Nov;90(11):6323-31
16105967
Bone. 2007 Jan;40(1):182-8
16935041